Brief: Genscript Biotech Says Legend Biotech Corp On 11 Feb Was Informed By U.S. FDA Its Phase 1 Clinical Trial For Lb1901 Has Been Placed On Clinical Hold

Genscript Biotech

15/02/2022 15:27

Feb 15 (Reuters) - Genscript Biotech Corp  1548.HK :
    * LEGEND BIOTECH CORP ON 11 FEB WAS INFORMED BY U.S. FDA ITS
PHASE
1 CLINICAL TRIAL FOR LB1901 HAS BEEN PLACED ON CLINICAL HOLD
    * DOSED PATIENT HAS NOT EXPERIENCED DRUG-RELATED SERIOUS
ADVERSE
EVENTS (SAES) AND IS BEING MONITORED IN ACCORDANCE WITH PROTOCOL

Source text for Eikon:  ID:nHKS2fG2PG 
Further company coverage:  1548.HK 

 ((Reuters.Briefs@thomsonreuters.com;))